Rosenberg, Ari J. http://orcid.org/0000-0001-5908-0939
Agrawal, Nishant http://orcid.org/0000-0002-1361-3231
Pearson, Alexander T. http://orcid.org/0000-0003-2801-7456
Gooi, Zhen
Blair, Elizabeth
Portugal, Louis
Cursio, John F.
Juloori, Aditya
Chin, Jeffrey
Rouse, Kathryn
Villaflor, Victoria M.
Seiwert, Tanguy Y.
Izumchenko, Evgeny
Lingen, Mark W.
Haraf, Daniel J.
Vokes, Everett E.
Article History
Received: 22 March 2022
Revised: 19 July 2022
Accepted: 29 July 2022
First Online: 9 August 2022
Competing interests
: AJR: consulting/advisory: EMD-Serono, Nanobiotix, Galectin Therapeutics, Privo Technologies. NA: stock options: Privo Technologies. ATP: consulting/advisory: Prelude, Abbvie, Elevar, Ayala; stock options: Privo Technologies; research funding: Abbvie, Kura Oncology. AJ: consulting: Isoray. Research funding: AstraZeneca. VMV: Stock: J&J. Research funding: Takeda. TS: research funding: BMS, AstraZeneca, Genentech, Nanobiotix, Merck. Honoraria: Merck, Nanobiotix. Consulting/advisory: Innate, Regeneron, Vir, Merck, Nanobiotix, BostonGene EEV: consulting/advisory: AstraZeneca, BeiGene, BioNTech, Eli Lilly, EMD-Serono, Genentech, GlaxoSmithKline, Novartis. The remaining authors declare no competing interests.
: This study was conducted in accordance with the Declaration of Helsinki and was approved by the University of Chicago institutional review board. Furthermore, written consent was obtained from all participants.
: Not relevant.